knowledge -WSS

knowledge

author：explore 2025-09-27 13:03:45 - browse：922

Richard Neal(D-MA), Rep. Frank Pallone (D-NJ),Rep. John Yarmuth (D-KY), Rep. Bobby Scott (D-VA) and House Minority Leader Nancy Pelosi (D-CA) attend the weekly press conference in the Capitol building on July 20, 2017 in Washington, DC. They spoke to the media about the efforts to reform the health care bill. -- health policy coverage from STAT — Reps. Richard Neal (D-Mass.), Rep. Frank Pallone (D-N.J.), and Rep. John Yarmuth (D-Ky.) Joe Raedle/Getty Images

WASHINGTON — It’s drug pricing déjà vu: Just as they did in 2019, House Democrats are pushing a bill that would allow Medicare to negotiate dozens of drug prices a year, offer those prices to all insurers, and crack down on price hikes.

Unlike then, Democrats have a starting place: the new bill represents an expansion of the major drug pricing legislation the party passed last year. But the first round of drug price negotiations hasn’t even started yet, and the law is under attack from the pharmaceutical industry in court.

The Democratic leaders of three key House committees put forth the proposal Wednesday.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Ebola vaccine can save some who are already sick, per new study

focus

WSS

Having children helps parents live longer, especially after age 80

HHS names first

Tome Biosciences co

AMAs digital advisors table RPM coding reform proposal, again

Congress considering partial increase for doctor pay in Medicare

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Wikipedia

knowledge

hotspot

Duchenne breakthrough therapy leaves behind pioneering families

JPM 2024: Verve Therapeutics looks to mainstream genome editing

Drug repurposing or repositioning? The language matters

Here’s what’s in the FDA plan to include pregnant women in clinical trials

Malaria cases in Florida and Texas: Here’s what you need to know

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

New air purifier tech could be key to improving indoor air quality

The SUPPORT Act is critical to fighting the opioid crisis

23andMe had bad news about my health. I wish a person had delivered it

JPM 2024: FogPharma’s CEO unveils ‘contrarian’ plan in oncology

leisure time

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Why liver experts renamed NASH to MASH, and NAFLD to MASLD

Long Covid research funding gets a major boost from NIH

Artificial intelligence use in health care faces greater scrutiny in 2024

DeSantis can now import cheaper drugs. But will Biden get credit?

Readout Newsletter: Amylyx, Aurinia, and IQVIA

focus

focus

leisure time

Wikipedia